All In Biotech

Drug Trial Radar · NCT03066869

Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis

Open-label, Single-center, Prospective Study on the Efficacy and Safety of Repository Corticotropin Injection (H.P. ACTHAR GEL) in the Treatment of Adults With Non-infectious Retinal Vasculitis

Last checked: Nov 20, 2026Latest source record: Sep 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

40

Planned (sponsor's estimate)

Start

Mar 22, 2017

Primary completion

Feb 2020

Study completion Aug 2020

Sponsor

Lead sponsor
Ocular Immunology and Uveitis FoundationAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 1, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the short- and long-term efficacy and safety of Acthar for the treatment of adults with non-infectious retinal vasculitis.

Conditions

  • Uveitis, Posterior
  • Vasculitis Retinal

Interventions

  • H.P. ACTHAR GELDrug

    H.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue indicated for ophthalmic diseases.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of responders to Acthar at the end of treatment.Time frame: 24 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ocular Immunology & Uveitis Foundation

    Waltham, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.